LU92282I2 - Telmisartan et/ou ses sels pharmacologiquement acceptables - Google Patents

Telmisartan et/ou ses sels pharmacologiquement acceptables

Info

Publication number
LU92282I2
LU92282I2 LU92282C LU92282C LU92282I2 LU 92282 I2 LU92282 I2 LU 92282I2 LU 92282 C LU92282 C LU 92282C LU 92282 C LU92282 C LU 92282C LU 92282 I2 LU92282 I2 LU 92282I2
Authority
LU
Luxembourg
Prior art keywords
telmisartan
acceptable salts
pharmacologically acceptable
treatment
sartan
Prior art date
Application number
LU92282C
Other languages
English (en)
Other versions
LU92282I9 (fr
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37744125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92282(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of LU92282I2 publication Critical patent/LU92282I2/fr
Publication of LU92282I9 publication Critical patent/LU92282I9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU92282C 2006-10-06 2013-09-19 Telmisartan et/ou ses sels pharmacologiquement acceptables LU92282I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06121905A EP1908469A1 (fr) 2006-10-06 2006-10-06 Antagonistes du récepteur de l'angiotensine II pour traiter des désordres sistémiques des chats

Publications (2)

Publication Number Publication Date
LU92282I2 true LU92282I2 (fr) 2013-11-19
LU92282I9 LU92282I9 (fr) 2019-01-17

Family

ID=37744125

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92282C LU92282I2 (fr) 2006-10-06 2013-09-19 Telmisartan et/ou ses sels pharmacologiquement acceptables

Country Status (25)

Country Link
US (5) US8772278B2 (fr)
EP (5) EP1908469A1 (fr)
JP (5) JP5425631B2 (fr)
KR (2) KR101456151B1 (fr)
CN (6) CN109125730A (fr)
AR (1) AR063155A1 (fr)
BR (4) BR122013019535A2 (fr)
CA (1) CA2665435C (fr)
CL (2) CL2007002897A1 (fr)
CO (1) CO6180425A2 (fr)
CY (2) CY1114266T1 (fr)
DK (4) DK2420232T3 (fr)
ES (4) ES2565519T3 (fr)
HR (1) HRP20130696T1 (fr)
HU (4) HUE027399T2 (fr)
LU (1) LU92282I2 (fr)
MX (4) MX360150B (fr)
NL (1) NL300616I2 (fr)
NZ (3) NZ597648A (fr)
PL (4) PL2420232T3 (fr)
PT (1) PT2086535E (fr)
SI (1) SI2086535T1 (fr)
TW (3) TWI415605B (fr)
WO (1) WO2008040774A2 (fr)
ZA (1) ZA200901218B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1908469A1 (fr) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Antagonistes du récepteur de l'angiotensine II pour traiter des désordres sistémiques des chats
AR068814A1 (es) * 2007-08-29 2009-12-09 Orion Corp Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso
WO2010097501A2 (fr) * 2009-02-26 2010-09-02 Orion Corporation Traitement combiné
BRPI1013037A2 (pt) 2009-05-20 2019-09-24 Boehringer Ingelheim Ipharmaceuticals Inc "solução farmacêutica oral de telmisartan"
CN102283832B (zh) * 2011-09-09 2013-04-10 南京正宽医药科技有限公司 一种预防或治疗高血压肥胖患者的药物组合物及用途
SG10201609364QA (en) * 2012-05-18 2017-01-27 Luoda Pharma Pty Ltd Liquid formulation
DE102012018903A1 (de) 2012-09-26 2014-03-27 Elisabeth Kurth Brustglocke für die manuelle Laktation von Milch aus der weiblichen Brust
CN105233288A (zh) * 2015-09-28 2016-01-13 青岛云天生物技术有限公司 一种治疗或预防肥胖型高血压的药物组合物及其用途
JP6800633B2 (ja) * 2016-07-04 2020-12-16 株式会社カネカ 非ヒト動物において腎機能の低下を抑制する方法
US10905676B2 (en) * 2017-07-07 2021-02-02 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1023027B (de) 1953-07-10 1958-01-23 Hoffmann La Roche Verfahren zur Herstellung von Polyendialdehyden
JPS5671074A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4448778A (en) 1981-08-03 1984-05-15 Ici Americas Inc. Maltitol containing gel base systems
CA1334092C (fr) 1986-07-11 1995-01-24 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii
CA1338238C (fr) 1988-01-07 1996-04-09 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii et combinaisons de ces imidazoles avec des diuretiques et des anti-inflammatoires non steroidiens
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
EP0443983B1 (fr) 1990-02-19 1996-02-28 Ciba-Geigy Ag Composés acylés
PT97078B (pt) 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IE912956A1 (en) 1990-09-10 1992-03-11 Abbott Lab Angiotensin ii receptor antagonists
GB9027210D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US6028091A (en) 1990-12-14 2000-02-22 Smithkline Beecham Plc Medicament
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5591762A (en) 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
DE69325574T2 (de) 1992-04-13 2000-03-16 Zeneca Ltd ANGIOTENSIN-II-ANTAGONISTEN GEGEN ERKRANKUNGEN; DIE MIT EINER EINGESCHRäNKTEN; NEURONALEN LEITUNGSGESCHWINDIGKEIT VERBUNDEN SIND, INSBESONDERE DIABETISCHE NEUROPATHIE
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
WO1995026188A1 (fr) 1994-03-29 1995-10-05 Merck & Co., Inc. Traitement de l'atherosclerose
CN1181019A (zh) * 1995-04-07 1998-05-06 诺瓦蒂斯有限公司 含有贝那普利或贝那普利拉和维沙坦的药物组合物
CA2257946A1 (fr) * 1996-06-24 1997-12-31 Merck & Co., Inc. Composition a base d'enalapril et de losartan
JPH11315034A (ja) * 1998-03-04 1999-11-16 Takeda Chem Ind Ltd アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途
BR9908474A (pt) 1998-03-04 2000-12-05 Takeda Chemical Industries Ltd Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica
US6204281B1 (en) * 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
DE19901921C2 (de) 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels
US6358986B1 (en) 1999-01-19 2002-03-19 Boehringer Ingelheim Pharma Kg Polymorphs of telmisartan
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
CA2424770A1 (fr) * 2000-10-06 2003-04-03 Takeda Chemical Industries, Ltd. Preparations solides
WO2002092081A1 (fr) 2001-05-14 2002-11-21 Merck & Co., Inc. Methode de traitement
WO2003013609A1 (fr) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Medicaments a liberation continue
DE10153737A1 (de) 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US6737432B2 (en) 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
JP2005531558A (ja) * 2002-05-17 2005-10-20 ノバルティス アクチエンゲゼルシャフト 心筋梗塞の二次予防のためのアンギオテンシンＩＩ受容体ブロッカーおよびβブロッカーの組合せ
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
JP2006516020A (ja) * 2002-08-28 2006-06-15 キュリス インコーポレイテッド 慢性腎不全の治療におけるモルフォゲン及びａｃｅ阻害薬の共投与
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10244681A1 (de) 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US20050187262A1 (en) * 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
EP1579862A1 (fr) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Utilisation des inhibiteurs de PDE III pour la réduction de la taille du coeur chez des mammifères souffrant d'insufficances cardiaques
WO2005123070A1 (fr) * 2004-06-09 2005-12-29 Fibrogen, Inc. Double blocage du systeme renine-angiotensine reduisant les niveaux du facteur de croissance du tissu conjonctif dans la nephropathie diabetique
CN1602960A (zh) * 2004-07-23 2005-04-06 海南国栋药物研究所有限公司 一种防治心脑血管病及糖尿病等代谢综合症的复合制剂
CN100364532C (zh) * 2004-09-30 2008-01-30 江苏恒瑞医药股份有限公司 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
CA2582049C (fr) * 2004-11-05 2010-08-24 Boehringer Ingelheim International Gmbh Comprime bicouche contenant du telmisartan et de l'amlodipine
CN1813707A (zh) * 2004-12-01 2006-08-09 鲁南制药集团股份有限公司 用于治疗高血压的含有单硝酸异山梨酯的药物组合物
US20070026026A1 (en) * 2005-08-01 2007-02-01 David Delmarre Oral liquid losartan compositions
EP1908469A1 (fr) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Antagonistes du récepteur de l'angiotensine II pour traiter des désordres sistémiques des chats
EP1970053A1 (fr) 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Composition pharmaceutique
BRPI1013037A2 (pt) 2009-05-20 2019-09-24 Boehringer Ingelheim Ipharmaceuticals Inc "solução farmacêutica oral de telmisartan"

Also Published As

Publication number Publication date
MX360147B (es) 2018-10-24
CN101522191B (zh) 2012-05-16
PL2420232T3 (pl) 2016-06-30
EP1908469A1 (fr) 2008-04-09
PL2420233T3 (pl) 2016-07-29
NZ597648A (en) 2013-05-31
WO2008040774A3 (fr) 2008-07-10
EP2086535B1 (fr) 2013-05-22
CO6180425A2 (es) 2010-07-19
CY2013037I1 (el) 2015-11-04
JP5899165B2 (ja) 2016-04-06
US20080146543A1 (en) 2008-06-19
EP2420232A3 (fr) 2012-05-02
ES2567041T3 (es) 2016-04-19
PL2420231T3 (pl) 2016-07-29
US9585873B2 (en) 2017-03-07
US20170128423A1 (en) 2017-05-11
HUE027399T2 (en) 2016-09-28
EP2420231A3 (fr) 2012-04-11
EP2420231A2 (fr) 2012-02-22
US8772278B2 (en) 2014-07-08
MX2009002340A (es) 2009-03-23
BR122013019533A2 (pt) 2015-07-14
MX360150B (es) 2018-10-24
CA2665435C (fr) 2016-03-29
BR122013019534A2 (pt) 2015-07-14
SI2086535T1 (sl) 2013-09-30
CN105148272A (zh) 2015-12-16
TWI539950B (zh) 2016-07-01
BR122013019535A2 (pt) 2015-07-14
ES2425482T3 (es) 2013-10-15
KR101529541B1 (ko) 2015-06-17
TWI415605B (zh) 2013-11-21
EP2086535A2 (fr) 2009-08-12
CY1114266T1 (el) 2015-11-04
US9949954B2 (en) 2018-04-24
US10357479B2 (en) 2019-07-23
CN102580095A (zh) 2012-07-18
KR20140088601A (ko) 2014-07-10
AU2007304216A1 (en) 2008-04-10
NZ609533A (en) 2014-08-29
JP2017122115A (ja) 2017-07-13
HUS1300062I1 (hu) 2013-11-28
JP6337170B2 (ja) 2018-06-06
KR101456151B1 (ko) 2014-11-04
KR20090080954A (ko) 2009-07-27
DK2086535T3 (da) 2013-07-22
JP2013216708A (ja) 2013-10-24
ES2565519T3 (es) 2016-04-05
ES2562182T3 (es) 2016-03-02
JP2010505796A (ja) 2010-02-25
CL2007002897A1 (es) 2008-03-07
TW201402115A (zh) 2014-01-16
HRP20130696T1 (hr) 2013-09-30
CN101522191A (zh) 2009-09-02
CN114344293B (zh) 2024-04-19
TW201332547A (zh) 2013-08-16
PL2086535T3 (pl) 2013-10-31
US9308197B2 (en) 2016-04-12
WO2008040774A2 (fr) 2008-04-10
HUE027280T2 (en) 2016-09-28
CY2013037I2 (el) 2015-11-04
TW200831078A (en) 2008-08-01
MX360148B (es) 2018-10-24
TWI539949B (zh) 2016-07-01
HUS1800044I1 (hu) 2018-12-28
CL2012001349A1 (es) 2012-10-12
ZA200901218B (en) 2010-03-31
US20140288138A1 (en) 2014-09-25
EP2420233A2 (fr) 2012-02-22
EP2420232A2 (fr) 2012-02-22
DK2420232T3 (en) 2016-03-07
CN109125730A (zh) 2019-01-04
CN114344293A (zh) 2022-04-15
DK2420233T3 (en) 2016-04-11
JP6151123B2 (ja) 2017-06-21
LU92282I9 (fr) 2019-01-17
NL300616I2 (fr) 2016-06-01
AR063155A1 (es) 2008-12-30
CN102580095B (zh) 2015-12-09
EP2420233A3 (fr) 2012-04-18
US20130190373A1 (en) 2013-07-25
JP5425631B2 (ja) 2014-02-26
US20180193317A1 (en) 2018-07-12
AU2007304216B2 (en) 2013-06-13
CA2665435A1 (fr) 2008-04-10
JP2016094436A (ja) 2016-05-26
DK2420231T3 (en) 2016-04-11
CN102512678A (zh) 2012-06-27
EP2420233B1 (fr) 2016-01-13
EP2420232B1 (fr) 2016-01-06
JP2013216709A (ja) 2013-10-24
NZ576109A (en) 2012-02-24
BRPI0718041A2 (pt) 2015-05-12
PT2086535E (pt) 2013-08-22
EP2420231B1 (fr) 2016-01-13

Similar Documents

Publication Publication Date Title
LU92282I2 (fr) Telmisartan et/ou ses sels pharmacologiquement acceptables
CL2008003595A1 (es) Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central.
CY1117958T1 (el) Ρυθμιστης υποδοχεα ανδρογονων για τη θεραπευτικη αντιμετωπιση του καρκινου του προστατη και νοσων σχετιζομενων με υποδοχεα ανδρογονων
BRPI0714315B8 (pt) arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende
CY1112751T1 (el) Μεθοδος διαμορφωσης του συζευγμενου με πρωτεϊνη g υποδοχεα gpr119 και επιλεγμενες ενωσεις
WO2008007211A8 (fr) Composés de carboxyamide bicycliques à n-bicycloalkyle substitué
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
WO2007088489A3 (fr) Préparation pharmaceutique contenant: un agoniste opioïde central, un antagoniste opioïde central, et un antagoniste opioïde périphérique, et sa méthode d'obtention
BRPI0411699A (pt) compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos
NO20082894L (no) Metode for behandling av kognitiv dysfunksjon
HK1140692A1 (en) Pharmaceutical composition
NO20085051L (no) Behandling av gastrointestinale forstyrrelser med CGRP-antagonister
BRPI0921097A2 (pt) composto derivado de pirazol-3 carboxamida com atividade de antagonista de receptor 5-ht2b, agente preventivo ou terapêutico, composição farmacêutica e uso do composto ou seu sal farmaceuticamente aceitável e método ou prevenção ou tratamento.
ME00571A (en) Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
WO2008021048A3 (fr) Procédés et compositions fondés sur l'adp-ribosyltransférase
MX2009000762A (es) 4-arilalcoximetil-4-fenil piperidinas y su uso como antagonistas del receptor de neuroquinina para el tratamiento de trastornos del sistema nervioso central.
UA108200C2 (uk) Лікарські форми та способи застосування ектопаразитоцидів
MY153292A (en) Benzimidazole carbamate composition
MX2009012179A (es) Uso de inhibidores de desacetilasa de histona (hdac) para el tratamiento de melanoma.
ITFI20060286A1 (it) Metodo e dispositivo per la cura di unghie incarnite.